Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia

Sci Rep. 2017 Mar 28:7:45176. doi: 10.1038/srep45176.

Abstract

Gut-derived bacterial lipopolysaccharide (LPS) and subsequent hepatic toll-like receptor 4 (TLR4) activation have been recognized to be involved in the onset of diet-induced nonalcoholic fatty liver disease (NAFLD), but little is known about the variation of LPS and TLR4 during the progression of NAFLD. Probiotics were able to inhibit proliferation of harmful bacteria and improve gastrointestinal barrier function. However, it's unclear whether LPS/TLR4 is involved in the protection effect of probiotics on NAFLD. In this study, we described characteristic of gut microbiota structure in the progression of NAFLD, and we also analyzed the relationship between gut microbiota and LPS/TLR4 in this process. Furthermore, we applied probiotics intervention to investigate the effect of probiotics on gut flora structure, intestinal integrity, serum LPS, liver TLR4 and liver pathology. Our results showed that serum LPS and liver TLR4 were highly increased during progression of NAFLD, with gut flora diversity and gut mircobiological colonization resistance (B/E) declining. Furthermore, probiotics could improve gut microbiota structure and liver pathology. Probiotics could also downregulate serum LPS and liver TLR4. Our results suggested that both gut flora alteration and endotoxemia may be involved in the progression of NAFLD. Probiotics may delay the progression of NAFLD via LPS/TLR4 signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Endotoxemia / prevention & control*
  • Endotoxemia / therapy
  • Gastrointestinal Microbiome*
  • Intestinal Mucosa / metabolism
  • Intestines / microbiology
  • Lipopolysaccharides / blood
  • Liver / metabolism
  • Male
  • Non-alcoholic Fatty Liver Disease / prevention & control*
  • Non-alcoholic Fatty Liver Disease / therapy
  • Probiotics / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Toll-Like Receptor 4 / metabolism

Substances

  • Lipopolysaccharides
  • Tlr4 protein, rat
  • Toll-Like Receptor 4